The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | Highlights from EBMT 2022
Markéta Marková, MD, PhD, Institute of Haematology and Blood Transfusion, Prague, Czech Republic, shares her highlights from the EBMT meeting. Dr Marková talks on a study comparing autologous hematopoietic stem cell transplantation (autoHSCT) with chimeric antigen receptor T-cell (CAR-T) therapy in second-line in lymphoma, as well as a lecture about VEXAS syndrome. Dr Marková also mentions a session on transplant decisions and novel drugs in myeloproliferative neoplasms (MPNs). Finally, Dr Marková mentions a study evaluating lenalidomide and azacitidine in relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as a presentation on engineered T-cells for graft-versus-host disease (GvHD). This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
